Roche takes on Loxo, Bayer in gene-defined cancer class
Sunday, October 21, 2018 - 05:00
in Health & Medicine
Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.